Alice Melão, MSc,  —

A mechanism triggered by the activation of two specific proteins called JAK2 and STAT3 was found to contribute to the damaging cellular transformations that occur in idiopathic pulmonary fibrosis (IPF), a study reports. Blocking this signaling pathway reduced the levels of lung damage in a rat model of IPF,…

A new mobile app called PF Health has been launched to help patients with pulmonary fibrosis track their symptoms and share that information with their healthcare providers. The PF Health app resulted from collaborative work of the Pulmonary Fibrosis Foundation (PFF) and monARC Bionetworks, and aims to empower…

Galapagos is planning to launch a Phase 2 clinical trial for its treatment candidate GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF). Expected to begin in the second half of 2018, the PINTA trial will evaluate the safety and effectiveness of this investigational therapy at several clinical sites in…

The patientMpower digital healthcare app now offers a “share” tool that allows patients with pulmonary fibrosis and like conditions to easily keep caregivers, friends, and family members aware of their progress, according to a blog on the company’s website. The interactive mobile platform — the basis of the…

A pulmonologist’s characteristics — such as the nature of the practice and previous treatment experience — can influence when anti-fibrotic therapy use is initiated in newly diagnosed idiopathic pulmonary fibrosis (IPF)  patients, a study based on a U.S. survey found. This finding adds to an understanding of the factors, besides patient preference,…

PBI-4050, Prometic Life Sciences’ treatment candidate, can prevent lung fibrosis progression in patients with idiopathic pulmonary fibrosis (IPF) when used alone or in combination with Ofev (nintedanib), Phase 2/3 trial data shows. Data from the trial were the subject of an oral presentation at the American…

At the 2nd Annual IPF Summit in San Francisco this summer, academic and biopharma experts in idiopathic pulmonary fibrosis (IPF) will again gather to discuss the latest developments in the field. Taking place Aug. 20-22, the conference aims to close the translational gap between preclinical data and clinical outcomes, a…

The University of Virginia recently launched the Fibrosis Initiative, a platform intended to support and mobilize researchers to collaborate and conduct studies focused on fibrosis. This program is expected to expand knowledge on fibrosis and lead to potentially groundbreaking discoveries that could open up new therapeutic opportunities. “In many…

AdAlta has changed the structure of its lead therapy candidate for AD-114, for the treatment of pulmonary fibrosis. The new product, renamed AD-214, has enhanced activity and improved stability compared to AD-114, allowing a better outcome, according to AdAlta. AD-214 retains key features of its precursor, as it…

A lung-scarring disease that affects preterm infants has a tissue repair signaling problem seen in idiopathic pulmonary fibrosis, Vanderbilt University researchers report. The discovery increases scientists’ understanding of the mechanisms underlying bronchopulmonary dysplasia and IPF. It also raises the possibility of treating both disorders by targeting the signaling dysfunction. Researchers published…